The FDA settlement failed to clarify the future of Philips' ...

The FDA settlement failed to clarify the future of Philips' respiratory business, leaving investors in the dark. The ongoing crisis, including lawsuits and a Justice Department investigation, continues to overshadow Philips. The gradual restoration of Philips's legal and operational health could present an opportunity for long-term investors, but this is expected to take years.